Recent news about BioSynthema Inc.

Top Stories

  • 10/15/2007
    BioSynthema and Covidien Imaging Solutions sign exclusive agreements for cancer therapy technology.
  • 5/7/2007
    BioSynthema signs agreement with Erasmus Medical Centre, Rotterdam, The Netherlands for exclusive rights to clinical study data for therapy to treat neuroendocrine tumors.
  • 4/18/2007
    BioSynthema signs collaboration agreement with Demokritos National Centre for Scientific Research, and Erasmus Medical Centre to develop radiolabeled small molecules for use in oncology.
  • 5/1/2005
    BioSynthema signs license agreement with University of Bern, University Hospital Basel, and Erasmus Medical Centre, for exclusive rights to new somatostatin receptor targeted peptides.
  • 1/1/2004
    BioSynthema Awarded NCI SBIR phase I grant to develop new receptor targeted molecules using RGD-linked somatostatin peptides.